Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 ...
Business Insider10d
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
About the Grace Therapeutics Asset Portfolio GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet ...
Grace Therapeutics, Inc.: Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRI ...
Morningstar13d
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle ...
Business Insider13d
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
About GTx-104 GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique ...
Grace Therapeutics, Inc.: Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...
Morningstar10d
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
About the Grace Therapeutics Asset Portfolio GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet ...
Mena FN13d
Grace Therapeutics Announces Private Placement Financing Of Up To $30 Million
About GTx-104 GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique ...
Nasdaq13d
Grace Therapeutics Secures Up to $30 Million in Financing Led by Nantahala Capital and ADAR1 Partners for GTx-104 Development
GTx-104 is a novel injectable formulation of nimodipine being developed for IV infusion to treat aneurysmal Subarachnoid Hemorrhage (aSAH) patients. Proceeds will be used for general corporate ...
Yahoo Finance13d
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal Subarachnoid Hemorrhage (aSAH) patients, today announced that it has ...